Table 1. Data set properties for 10 clinical end points.

Data set code	End point code	End point description	Microarray platform	Training set				Validation set
				Number of samples	Positives (N+)	Negatives (N−)	N+/N− ratio	Number of samples	Positives (V+)	Negatives (V−)	V+/V− ratio
Breast cancer (BR)a	D	Preoperative treatment response (pCR)	Affymetrix Human U133A	130	33	97	0.34	100	15	85	0.18
	E	Estrogen receptor status (erpos)		130	80	50	1.6	100	61	39	1.56
Multiple myeloma (MM)b	F	Overall survival milestone outcome (OS, 730-day cutoff)	Affymetrix Human U133Plus 2.0	340	51	289	0.18	214	27	187	0.14
	G	Event-free survival milestone outcome (EFS, 730 cutoff)		340	84	256	0.33	214	34	180	0.19
	H	Class label is the sex of the patient used as ‘positive' control end point		340	194	146	1.33	214	140	74	1.89
	I	Class label is randomly assigned and used as ‘negative' control end point		340	200	140	1.43	214	122	92	1.33
Neuroblastoma (NB)c	J	Overall survival milestone outcome (OS, 900-day cutoff)	Different versions of Agilent human microarrays	238	22	216	0.10	177	39	138	0.28
	K	Event-free survival milestone outcome (EFS, 900-day cutoff)		239	49	190	0.26	193	83	110	0.75
	L	Class label is the sex of the patient and used as ‘positive' control end point		246	145	101	1.44	231	133	98	1.36
	M	Class label is randomly assigned and used as a ‘negative' control end point		246	145	101	1.44	253	143	110	1.30

^aProvided by the University of Texas MD Anderson Cancer Center (Houston, TX, USA).²

^bProvided by the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (Little Rock, AR, USA).³

^cProvided by the Children's Hospital of the University of Cologne, Germany.⁴